Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Johnson & Johnson/IsoStent

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/IsoStent: J&J's Cordis unit bolsters its coronary stent pipeline through the acquisition of the BX Stent from privately held IsoStent. Currently in development, the BX utilizes a "slotted tube" design to provide "greater flexibility" during implantation and "superior radial strength following deployment," J&J maintains. The device, for which J&J previously had obtained an option for international marketing rights, is intended for use in saphenous vein grafts as well as "normal stenting procedures." Also acquired is development-stage technology for catheter-based intravascular radiation therapy to help prevent restenosis. J&J and Belmont, California-based IsoStent will continue to collaborate under a March 1996 agreement to develop radioactive versions of J&J's Palmaz-Schatz coronary stent ("The Gray Sheet" April 22, 1996, I&W-1)...

You may also be interested in...



Combo Product Excitement: Large Players On Look-Out For Early-Stage Deals

Heightened corporate interest in innovative drug-delivery technologies offers greater opportunities for small device firms to attract larger company investment, venture capitalists say

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel